| __timestamp | Alpine Immune Sciences, Inc. | Opthea Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 2287709 | 2652041 |
| Thursday, January 1, 2015 | 6844000 | 2361587 |
| Friday, January 1, 2016 | 8586000 | 4472869 |
| Sunday, January 1, 2017 | 6079000 | 5030957 |
| Monday, January 1, 2018 | 8362000 | 4988941 |
| Tuesday, January 1, 2019 | 9467000 | 5196412 |
| Wednesday, January 1, 2020 | 10899000 | 6652774 |
| Friday, January 1, 2021 | 14560000 | 18418247 |
| Saturday, January 1, 2022 | 17968000 | 24827066 |
| Sunday, January 1, 2023 | 22222000 | 41896408 |
| Monday, January 1, 2024 | 15488619 |
Unleashing the power of data
In the competitive landscape of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Opthea Limited and Alpine Immune Sciences, Inc. from 2014 to 2023. Over this period, Opthea's SG&A expenses surged by over 1,480%, peaking in 2023, while Alpine's expenses increased by approximately 872%. Notably, Opthea's expenses in 2023 were nearly double those of Alpine, highlighting a significant divergence in financial strategies. The data reveals a consistent upward trend for both companies, with Opthea showing a more aggressive increase. This could indicate a strategic investment in growth and expansion. However, the absence of data for Alpine in 2024 suggests a need for cautious interpretation. Investors and stakeholders should consider these trends when evaluating the companies' operational efficiencies and future prospects.
Who Optimizes SG&A Costs Better? Zoetis Inc. or Opthea Limited
Breaking Down SG&A Expenses: Dr. Reddy's Laboratories Limited vs Alpine Immune Sciences, Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Alpine Immune Sciences, Inc.
R&D Insights: How Opthea Limited and Alpine Immune Sciences, Inc. Allocate Funds
SG&A Efficiency Analysis: Comparing Opthea Limited and Axsome Therapeutics, Inc.
Opthea Limited vs TG Therapeutics, Inc.: SG&A Expense Trends
Opthea Limited and Supernus Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Alpine Immune Sciences, Inc. or CymaBay Therapeutics, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Alpine Immune Sciences, Inc. vs Vericel Corporation
Selling, General, and Administrative Costs: Alpine Immune Sciences, Inc. vs Supernus Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and Galapagos NV
Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and BioCryst Pharmaceuticals, Inc.